Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: A retrospective cohort study

Rheumatology

Volumn 46, Issue 2, 2007, Pages 265-272

  Rahme, Elham ^a   Bardou, M ^b   Dasgupta, K ^a   Toubouti, Y ^a   Ghosn, J ^a   Barkun, A N ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Administrative databases; Aspirin; Cox 2 inhibitors; Elderly; Gastrointestinal bleeding; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARTHROTEC; CELECOXIB; CORTICOSTEROID; DICLOFENAC; ETODOLAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PROTON PUMP INHIBITOR; ROFECOXIB;

AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA BASE; DRUG EXPOSURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUODENUM BLEEDING; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PAIN; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STOMACH HEMORRHAGE;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; PYRAZOLES; QUEBEC; RETROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 33846685307     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel223     Document Type: Article

References (63)

1. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998;104:23S-9S.
2. MacDonald TM. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology 2000;39(Suppl 2):S13-20.
3. Patrono C. Aspirin: New cardiovascular uses for an old drug. Am J Med 2001; 110:62S-65S.
4. Mahe I, Leizorovicz A, Caulin C, Bergmann JF. Aspirin for the prevention of cardiovascular events in the elderly. Drugs Aging 2003;20:999-1010.
5. Patrono C, Rodriguez LAG, Landofi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353: 2373-83.
6. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. Clin Invest 1982;69:1366-72.
7. Patrono C, Coller B, FitzGerald GA, Hirsch J, Roth G. Platelet-active drugs; the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:234S-64S.
8. Cox ER, Frisse M, Behm A, Fairman KA. Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med 2004;164:1243-6.
9. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal anti-inflammatory drugs, the risk of myocardial infarction in the general population. Circulation 2004;109:3000-6.
10. Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial. http://www.nih.gov/news/pr/dec2004/ od-20.htm. 2004. National Institutes of Health, US, Department of Health and Human Services.
11. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995;310:827-30.
12. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis. Br Med J 2000;321:1183-7.
13. MacDonald TM, Pettitt D, Lee FH, Schwartz JS. Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes. Rheumatology 2003;42:3-10.
14. Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/ perforation: An overview of epidemiologic studies published in the 1990s. Arch Int Med 2000;160:2093-9.
15. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: A new model applied to chronic NSAID use. Pain 2000;85:169-82.
16. Williams HJ, Ward JR, Egger MJ et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993;36:1196-206.
17. Sorensen HT, Mellemkjaer L, Blot WJ et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000;95:2218-24.
18. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthriAis and rheumatoid arthritis: The CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
19. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials. Br Med J 2002;325:619.
20. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.
21. Laine L, Bombardier C, Hawkey CJ et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterol 2002;123:1006-12.
22. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
23. American College of Rheumatology Committee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15.
24. Tannenbaum H, Peloso PM, Russell AS, Marlow B. An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis. Can J Clin Pharmacol 2000;7(Suppl A)4A-16A.
25. Hunt RH, Barkun AN, Baron D et al. Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: Defining the role of gastroprotective agents. Can J Gastroenterol 2002;16:231-40.
26. Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclooxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004;19:197-208.
27. Pfizer statement on new information regarding cardiovascular safety of Celebrex. http://www.pfizer.com/are/investors_releases/2004pr/ mn_2004_1217.cfm. 2005.
28. Linton MF, Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol 2004;4:116-23.
29. White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003;92:411-8.
30. Solomon DH, Schneeweiss S, Glynn RJ et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
31. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. The Lancet 2002;360:1071-3.
32. Catella-Lawson IA, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
33. Kurth T, Glynn RJ, Walker AM et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003;108:1191-5.
34. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573-4.
35. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: A reappraisal. Arthritis Rheum 2003;48:12-20.
36. http://www.ramq.gouv.qc.ca/ accessed March 21, 2006.
37. De Wals P, Trochet C, Pinsonneault L. Prevalence of neural tube defects in the province of Quebec, 1992. Can J Public Health 1999;90:237-9.
38. Rahme E, Marentette MA, Kong SX, LeLorier J. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated co-prescriptions of gastroprotective agents in an elderly population. Arthritis Care Res 2002;47:595-602.
39. Rahme E, Barkun AN, Toubouti Y, Bardou M. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterol 2003;125:404-12.
40. Rahme E, Pettit D, LeLorier J. Determinants and sequelae associated with acetaminophen utilization versus traditional NSAIDs in an elderly population. Arthritis Rheum 2002;46:3046-54.
41. Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: Retrospective cohort study of an elderly population. Arthritis Rheum 2000;43:917-24.
42. Mamdani M, Rochon PA, Juurlink DN et al. Observational study of upper gastrointestinal haernorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. Br Med J 2002;325:624.
43. Raiford DS, Gutthann SP, Rodriguez LAG. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan Hospital automated database. Epidemiol 1996;7:101-4.
44. Fleming T, Harrington D. Counting process and Survival analysis. New York, Wiley, 1991.
45. Barkun A, Bardou M, Marshall JK. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003;139:843-57.
46. Norgard B, Pedersen L, Johnsen SP et al. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: A population-based case-control study. Aliment Pharmacol Ther 2004;19:817-25.
47. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, Laupacis A. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. Br Med J 2004;328:1415-6.
48. Kimmey MB, Lanas A. Review article: Appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 2004;19(Suppl 1):60-5.
49. Wallace JL, Zamuner SR, Mcknight W, Dicay M et al. Aspirin, but not NO-releasing aspirin NCX4016 interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Am J Physiol Gastrointest Liver Physiol 2004;286:76-81.
50. Fiorucci S, Distrutti E, de Lima OM et al. Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB Journal 2003;17:1171-3.
51. Hochberg MC, Altman RD, Brandt KD et al. Guidelines for the medical management of osteoarthritis. Part II Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995;38:1535-46.
52. Nandurkar S, Talley NJ, Xia H, Mitchell H, Hazel S, Jones M. Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection. Arch Int Med 1998;158:1427-33.
53. Blum AL, Talley NJ, O'Morain C et al. Lack of effect of treating, Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998;339:1875-81.
54. Fiorucci S, Santucci L, Wallace JL et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci USA 2003;100:10937-41.
55. Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J. Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000;343:834-9.
56. Chey WD, Eswaren S, Howden CW, Inadomi JM, Fendrick AM, Scheiman JM. Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: Results of a national survey. Aliment Pharmacol Ther 2006;23:655-68.
57. American College of Rheumatology. Update of ACR guidelines for osteoarthritis: Role of the coxibs. Journal of Pain and Symptom Management 2002;32(Suppl 4):S31-4.
58. Price-Forbes AN, Callaghan R, Allen ME, Rowe IF. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. Rheumatol 2005;44:921-4.
59. Rahme E, Barkun A, Toubouti Y, Rochon S, LeLorier J. Do proton pump inhibitors infer additional gastrointestinal protection in patients given celcoxib. Pharmacoepidermiol Drug Saf 2005;14:S189.
60. Tamblyn R, Lavoie G, Petrella. L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
61. Savitz A. Interpreting epidemiologic evidence: Strategies for study design and analysis. Oxford University Press, New York, 2003.
62. Rahme E, Toubouti Y, Hunsche E. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada. Rheurnatology (Oxford) 3 February 2006 [Epub ahead of print].
63. Moride Y, Ducruet T, Rochon S, Lavoie F. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. Rheumatology 2003;42(Suppl 3):iIi17-22.